Company / SG&A Expense
Avalo Therapeutics, Inc. SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$22.9M
FY2025
5-year range
$10.3M / $24.7M
FY2021-FY2025
Trend
+32.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 9 years, ranging from $8M in FY2017 to $25M in FY2021.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of +5.6%.
Increased from $10M to $23M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +3.4%
- 5-Year CAGR
- +5.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +5.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 32.8% year-over-year.
- Peak sg&a expense was recorded in FY2021.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.9M | +32.8% |
| FY2024 | $17.2M | +67.4% |
| FY2023 | $10.3M | -50.3% |
| FY2022 | $20.7M | -16.0% |
| FY2021 | $24.7M | +41.6% |
| FY2020 | $17.4M | +72.1% |
| FY2019 | $10.1M | -3.7% |
| FY2018 | $10.5M | +32.4% |
| FY2017 | $7.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026